Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marlon Chagua

Internal Medicine Louisville, KY Medical Doctor

NPI 1407811870 CMS profile 62914

4001 Kresge Way Ste 236, Louisville, KY 40207

Open in the dashboard

General payments

$11,420

656 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marlon Chagua of Louisville, KY is reported in the CMS Open Payments database as having received $11,420 across 656 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,498 66
2024 General $1,775 86
2023 General $2,148 104
2022 General $1,550 80
2021 General $1,654 112
2020 General $1,353 95
2019 General $1,442 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marlon Chagua
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Marlon Chagua were reported at $1,498. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Marlon Chagua Internal Medicine median Middle half National median
2019 $1,442 $159 $48–$570 $163
2020 $1,353 $119 $33–$402 $114
2021 $1,654 $135 $37–$521 $132
2022 $1,550 $141 $42–$496 $149
2023 $2,148 $149 $45–$519 $160
2024 $1,775 $154 $47–$537 $164
2025 $1,498 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,339 55 payments
  2. Sunovion Pharmaceuticals Inc. $996 81 payments
  3. AbbVie, Inc. $917 72 payments
  4. Amgen Inc. $679 36 payments
  5. UCB, Inc. $673 27 payments
  6. Pfizer Inc. $655 45 payments
  7. GlaxoSmithKline, LLC. $631 34 payments
  8. Lilly USA, LLC $427 26 payments
  9. Novartis Pharmaceuticals Corporation $410 23 payments
  10. Sumitomo Pharma America, Inc. $394 25 payments
  11. Other $4,300 232 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,408 655 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $880 31 payments
  2. APTIOM $727 59 payments
  3. Repatha $612 32 payments
  4. TRELEGY ELLIPTA $589 31 payments
  5. Nayzilam $574 21 payments
  6. Otezla $532 33 payments
  7. VRAYLAR $468 42 payments
  8. GEMTESA $462 31 payments
  9. ELIQUIS $437 31 payments
  10. UBRELVY $403 27 payments
  11. Other $8,929 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 268 drugs

Part D claims

25,910

Median for Internal Medicine: 777

Drug cost

$2,022,533

Median for Internal Medicine: $73,373

Branded share of claims

23.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 700 $312,513
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 162 $119,903
Xtandi Enzalutamide Brand 11 $104,223
Jardiance Empagliflozin Brand 199 $99,568
Farxiga Dapagliflozin Propanediol Brand 152 $82,278
Trulicity Dulaglutide Brand 84 $80,623
Ozempic Semaglutide Brand 74 $77,045
Gemtesa Vibegron Brand 124 $56,245
Memantine Hcl Generic 581 $42,107
Xifaxan Rifaximin Brand 34 $34,364

The 10 drugs with the highest cost, of 268 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$247,104

Medicare's payments for the services billed

Medicare patients

415

Average age 76

Services billed

3,789

226 women, 189 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 60%
Alzheimer's or dementia 50%
Arthritis 49%
Diabetes 40%
Chronic kidney disease 39%
Ischemic heart disease 36%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Nayzilam
$360 — —
REXULTI
$165 13 —
VRAYLAR
$127 — —
FARXIGA
$104 152 —
Otezla
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

656 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record